BioHarvest Sciences Announces New Campus for Botanical Synthesis CDMO and Expansion of Manufacturing Capacity
BioHarvest Sciences Announces New Campus for Botanical Synthesis CDMO and Expansion of Manufacturing Capacity
- 80,000 Square Foot (7,500 Square Meter) Property includes 12 GMP Clean Rooms, Laboratory and Office space, and can accommodate expanded 50 Ton Manufacturing facility
- New Production Technologies Implemented at this Campus will serve to optimize the planned US-based 150-ton manufacturing facility
- 80,000 平方英尺(7,500 平方米)的物業包括 12 個 GMP 潔淨室、實驗室和辦公空間,可容納擴建的 50 噸製造設施
- 該園區實施的新生產技術將用於優化計劃中的位於美國的150噸製造工廠
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - April 16, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology process, today announced the signing of two agreements: an equipment purchase agreement for 12 state of the art GMP clean rooms, and a long term lease agreement for a new 80,000 square ft. facility in Yavne, Israel. The new facility houses industry leading clean rooms, as well as built-out laboratory space, offices and additional space capable of supporting a new 50 Ton manufacturing facility.
不列顛哥倫比亞省溫哥華和以色列雷霍沃特--(Newsfile Corp.,2024年4月16日)——開創其專利植物合成技術工藝的生物技術公司BioHarvest Sciences Inc.(CSE:BHSC)(OTCQB:CNVCF)(“BioHarvest” 或 “公司”)今天宣佈簽署兩項協議:12個最先進的GMP潔淨室的設備購買協議和長期租賃協議在以色列亞夫內建造一座佔地8萬平方英尺的新設施。新設施擁有行業領先的潔淨室,以及可支持新的 50 噸製造設施的建成實驗室空間、辦公室和額外空間。
Laboratory Spaces Inside New Yavne Corporate Campus
New Yavne 企業園區內的實驗室空間
The commercial term of the lease is for 78 months at a cost of 20.2 million shekels (USD5.5 Million), subjected to changes in the Israeli consumer price index over the entire term. The equipment purchase price is 13 Million shekels (USD3.6M). All equipment for the clean rooms has been installed and is ready for immediate operational use.
租賃的商業期限爲78個月,成本爲2,020萬謝克爾(550萬美元),視整個租期內以色列消費者物價指數的變化而定。設備購買價格爲1300萬謝克爾(360萬美元)。潔淨室的所有設備都已安裝完畢,可以立即投入使用。
This transaction gives Bioharvest immediate access to the required state of the art clean rooms and built out laboratories to accommodate the anticipated growth of the CDMO Business Unit. The facility has enough additional space to avail the building of a new 50 Ton manufacturing facility which is expected to be operational in H2 of 2025 to meet the forecasted demand of the Products Business Unit as well as to satisfy the initial large scale manufacturing requirements of CDMO customers. This new manufacturing facility will utilise upgraded equipment and technologies which the Company has been developing, representing the second generation of the Botanical Synthesis manufacturing process, designed to further improve production yields and efficiencies.
該交易使Bioharvest可以立即進入所需的最先進的潔淨室並建造了實驗室,以適應CDMO業務部門的預期增長。該工廠有足夠的額外空間來建造一個新的50噸製造工廠,該工廠預計將於2025年下半年投入運營,以滿足產品業務部門的預測需求,並滿足CDMO客戶最初的大規模製造需求。這座新的製造工廠將利用公司一直在開發的升級設備和技術,這些設備和技術代表了第二代植物合成製造工藝,旨在進一步提高產量和效率。
The Company expects that Rehovot facility Research & Development and corporate administrative offices will be moved to the new BioHarvest Campus in the next 6-9 months. In the future, this new Campus will house all R&D functions and the addition of a new manufacturing facility in 2025. It will also allow CDMO customers to experience the complete end-to-end botanical synthesis development and manufacturing service under one roof. The Company anticipates that new technologies successfully implemented in this new campus will optimize design of the 3rd generation production facility, which is expected to be built in the USA, with a 150 Ton capacity.
該公司預計,雷霍沃特設施的研發和公司行政辦公室將在未來6-9個月內遷至新的BioHarvest園區。未來,這個新園區將容納所有研發職能,並將在2025年增加一個新的製造工廠。它還將使CDMO客戶能夠在一個屋檐下體驗完整的端到端植物合成開發和製造服務。該公司預計,在這個新園區成功實施的新技術將優化3座園區的設計第三方 發電生產設施預計將在美國建造,產能爲150噸。
CEO Ilan Sobel stated: "We are pleased to announce our plans for a new corporate campus, which will consolidate our corporate, R&D and production footprints under one roof. This is a significant milestone that will allow us to support the anticipated growth of our CDMO services business while concurrently building the manufacturing capacity necessary to support the rapid growth of our products business.
首席執行官伊蘭·索貝爾表示:“我們很高興地宣佈我們建造新的企業園區的計劃,這將把我們的企業、研發和生產足跡整合到一個屋檐下。這是一個重要的里程碑,它將使我們能夠支持CDMO服務業務的預期增長,同時建立支持產品業務快速增長所需的製造能力。
"We were able to secure the facility lease and equipment purchase agreements on excellent terms. I look forward to continuing our steady cadence of operational execution in the months ahead as we strive to leverage the power of the plant kingdom to transform the pharmaceutical, cosmeceutical, nutraceutical, and food nutrition industries," concluded Sobel.
“我們能夠以優惠的條件獲得設施租賃和設備購買協議。我期待在未來幾個月繼續保持穩定的運營執行節奏,努力利用植物界的力量來改造製藥、藥品、營養品和食品營養行業,” 索貝爾總結道。
About BioHarvest Sciences Inc.
BioHarvest 科學公司簡介
BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit .
BioHarvest Sciences Inc.(CSE:BHSC)(場外交易代碼:CNVCF)(FSE:8MV)是植物合成領域的領導者,利用其專利技術平台培育植物基分子,無需種植底層植物。BioHarvest正在利用其植物合成技術在兩個主要垂直業務領域開發基於科學且經過臨床驗證的下一代治療解決方案;作爲代表尋求複雜分子的客戶的合同開發和生產組織(CDMO),以及作爲專有營養保健品健康和保健產品(包括膳食補充劑)的創造者。要了解更多信息,請訪問。
Forward-Looking Statements
前瞻性陳述
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Readers are cautioned that the construction schedule and output capacity of future manufacturing facilities may be impacted by future changes in product demand, capital constraints, or other market factors. Corporate initiatives to improve yields and efficiencies may not be successful, and forecasts for revenue, profitability, and product sales are subject to risks and uncertainties including changes in consumer preferences, inflationary pressures and supply disruptions.
本新聞稿中提供的信息可能包括基於管理層當前估計、信念、意圖和預期的前瞻性陳述,並且存在許多風險和不確定性,這些風險和不確定性可能導致實際業績與前瞻性陳述中描述的結果存在重大差異。提醒讀者,未來製造設施的施工進度和產能可能會受到未來產品需求變化、資本限制或其他市場因素的影響。企業提高收益率和效率的舉措可能不會成功,對收入、盈利能力和產品銷售的預測會受到風險和不確定性的影響,包括消費者偏好的變化、通貨膨脹壓力和供應中斷。
All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
所有前瞻性陳述本質上都是不確定的,實際結果可能會受到我們無法控制的許多重大因素的影響。讀者不應過分依賴前瞻性陳述。除了通過我們的定期管理層討論和分析披露外,BHSC無意更新前瞻性陳述披露。
This release is subject to CSE approval, and neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.
本新聞稿尚待CSE批准,加拿大證券交易所及其監管服務提供商均不對本新聞稿的充分性或準確性承擔責任。
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations & Director
+1 (604) 622-1186
info@bioharvest.com
BioHarvest 公司聯繫方式
投資者關係副總裁兼董事戴夫·瑞安
+1 (604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
+1 (949) 259-4987
BHSC@mzgroup.us
投資者關係聯繫人:
盧卡斯·A·齊默爾曼
董事總經理
MZ 集團-MZ 北美
+1 (949) 259-4987
BHSC@mzgroup.us